Introduction-It is believed that men diagnosed with prostate cancer and a low baseline serum testosterone (BST) may have more aggressive disease and it is frequently recommended they forego testosterone replacement therapy. We used two large phase III trials involving androgen deprivation therapy (ADT) and radiotherapy (EBRT) to assess the significance of a BST.
Introduction
Prostate cancer is the most commonly diagnosed non-cutaneous malignancy in the American male. A significant number of these men present with low or borderline baseline serum testosterone levels and some of are using testosterone supplements at the time of diagnosis. There are three challenges concerning the management of such patients. First, is the issue of how a low baseline serum testosterone (BST) influences prognosis. Second, whether there is reason to believe hormone replacement therapy should be discontinued and finally, when treatment is completed, whether replacement therapy should be reinstituted.
A number of retrospective studies have concluded that men with clinically localized prostate cancer presenting with a low BST level have a worse outcome. Several of these studies included men with metastatic disease and suggested that their poor outcome was a manifestation of an intrinsic state of androgen independence [1] [2] [3] [4] . Low BST levels have also been associated with poor outcomes in patients undergoing radical prostatectomy 5, 6 . These patients appeared to present with high-grade disease that was associated with a higher risk of recurrence 7, 8 . These studies supported an association between a low testosterone and more aggressive prostate cancer but did not include patients treated on prospective randomized trials 4, 7, 9 . In addition, treatment and follow-up were not standardized on these studies.
Not all studies support the assertion that a low BST is an adverse prognostic factor. For example, Armstrong et al. noted no relationship between baseline testosterone and biochemical failure 10. Among a group of 33 patients with metastatic prostate cancer treated with orchiectomy, the third with the lowest testosterone showed a better survival than the ones with a higher testosterone. Also of note, some studies suggest that a delay in the time to recovery of testosterone in patients managed with androgen deprivation therapy and radiation might be associated with a more favorable outcome 11 . This observation raises the possibility that patients with a low BST level might benefit because this low testosterone level may lead to delayed recovery of testosterone and a prolonged disease free period. This issue has particular relevance for men managed with androgen deprivation therapy (ADT) in combination with radiotherapy for intermediate and high-risk disease. For these men ADT is commonly prescribed for periods of four months to three years or even more, with little guidance as to how their testosterone levels should be managed when ADT is completed 12 .
Thus, there are conflicting studies regarding the significance of BST levels in patients with adenocarcinoma of the prostate. The studies alluded to tended to be relatively small, the patients heterogeneous, non-randomized, and most of these studies had relatively short follow-up. In an attempt to address this issue definitively, we pooled data from two large phase III randomized trials from Radiation Therapy Oncology Group (RTOG) involving ADT and external beam radiation therapy (EBRT) in an attempt to determine the prognostic significance of a low BST level.
Materials and Methods
RTOG 9202 and 9413 have been previously published and the details of those studies are found elsewhere 13 , 14 . Briefly, RTOG 9202 included approximately 1500 patients, half of whom (Arm 1) received 4 months of ADT and the other half (Arm 2) 28 months of ADT in combination with EBRT. RTOG 9413 had four arms studying the relationship between the sequence and the volume of radiotherapy (pelvic vs. no pelvic irradiation) in approximately 1300 patients treated for locally advanced prostate cancer. In both trials patients received nearly 7000 cGy. Patients who were surgically staged were ineligible for RTOG 9202, as were patients with distant metastasis. Additional criteria included: Karnofsky performance status ≥ 70, no prior hormonal therapy, radiation or chemotherapy and liver function tests ≤ 1.2 times upper limits of normal. Patients with histologically confirmed adenocarcinoma of the prostate, clinical stage T2c (bilobar) to T4, with no involved nodes in the common iliac or higher node chains, with Karnofsky performance score ≥70 and with pretreatment PSA less than 150 ng/ml were eligible.
For RTOG 9413 eligibility included histologically confirmed clinically localized (negative bone and CT scans) adenocarcinoma of the prostate with an elevated PSA ≤ 100 ng/ml. Patients were stratified by T stage: T1c, T2a vs T1b, T2b vs T2c-T4; PSA (≤ 30 vs > 30 ng/ ml) and Gleason Score (GS) (GS< 7 vs 7-10) and no prior hormonal therapy was allowed. Eligible patients were required to have an estimated risk of lymph node (LN) involvement >15%, based on the equation +LN = (2/3) PSA + [(GS − 6) × 10] 15 . Patients with T2c-T4 were also eligible if their GS ≥ 6 even if by the equation their risk did not reach 15% based on their risk as reported by Partin et al 16. A BST was required at the time of entry on this study and for the purposes of this analysis, we used data from all eligible patients for each trial with an available BST to determine the impact on outcome.
Statistical Methods
We compared the pretreatment characteristics and outcomes of patients with and without missing data by Chi-square test statistics to see if there was bias between the two patients groups. Chi-square test statistics were also used to compare pretreatment characteristics. We performed heterogeneity testing for this analysis to see if one estimate could be used to represent the combined data from different trials (homogeneous) or not (heterogeneous). Tests of heterogeneity of testosterone for group differences across arms (the stratification variable) were performed for overall survival (OS), distant metastasis (DM), biochemical failure (BF) and cause-specific survival (CSS) using Chi-square test statistics. If the arms are homogeneous, the pooled hazard ratio (HR) was used as the estimator for the combined data 17, 18 . The failure event of OS was a death due to any cause. Biochemical failure was defined using the "Phoenix Definition" and the failure event of cause-specific survival was a death related to prostate cancer or as a complication of protocol treatment 19. Distant metastasis was defined as clinical evidence of distant disease by any method. Time to failure is measured from the date of randomization to the date of the first failure event.
The Kaplan-Meier method was used to estimate the OS rate, and the log-rank test was used to test the difference between the treatments or categories in the univariate analysis 20 of OS. The cumulative incidence method was used to estimate the DM rate, BF rate, and CSS rate, and Gray's test was used to test the difference between the treatments or categories in the univariate analysis21 of these endpoints. Cox proportional hazards regression model was used for OS, and Fine and Gray's regression model was used for DM, BF, and CSS 22 23 . Baseline testosterone (BST) levels were initially divided into tertiles, but because most published series have implied that very low baseline testosterone levels were more likely to be clinically relevant, the lowest tertile was further subdivided into two. Thus four categories were generated: "Very low baseline testosterone" (VLBST) group that had a ≤ 16.5 th percentile of BST, the "Low testosterone" (LBST) group had a testosterone that >16.5 th percentile and ≤ 33 rd percentile, the "Average testosterone" (ABST) group had a level that was > 33 rd percentile and ≤ 67 th percentile, and "High testosterone" (HBST) group that was greater than > 67 th percentile. As an additional exploratory exercise to determine if men with even lower levels of testosterone, i.e., the lowest 5%, might have more aggressive disease we compared this group (n=124) with the rest of patients (n=2354). However, since this did not alter our findings the data are not shown.
Statistical Analysis System (SAS Institute, Cary, NC) was used for all statistical analyses except Gray's testing and Fine and Gray's modeling which was analyzed using R software. A p-value <0.05 was considered as statistically significant.
Results
A total of 223 (8.3%) patients were excluded from 2701 patients; 129 of the 223 patients were excluded due to missing testosterone information. In total, complete data was available for 2,478 (92%) of the patients from RTOG 9202 and 9413. Table 1 shows the outcomes between the groups with and without missing data. The results of the analyses show that there are not statistically significantly differences between the two groups (p-values >0.05). To address the trend for an association between Gleason Score and BST (p=0.07, Table 1) we performed additional statistical evaluations. Pearson correlation between BST group and GS was −0.0196, this indicates that there is no strong directional correlation between the two. Also the p-value from F-test to see if there is a mean BST difference among three GS groups is 0.875, which indicates that there is no difference with respect to mean BST among three GS group. Therefore imputation was not done for this analysis.
There were 408 patients in the VLBST group. This group made up the bottom 16.5% of patients with a serum testosterone less than or equal to 248 ng/dl (mean=189.5 ng/dl). The LBST group had 415 patients and their serum testosterone was greater than 248 but less than or equal to 314 ng/dl (mean= 282.2 ng/dl). There were 845 patients in the ABST group and had a level that was greater than 314 to 437 ng/dl (mean= 372 ng/dl) and the HBST group had 810 patients whose serum testosterone was greater than 437 ng/dl (mean= 576 ng/dl) ( Table 2 ).
There was no statistical bias among the four BST group and age, Gleason score, or PSA. However, there is a statistically significant difference in KPS and treatment arm among the four BST groups (Table 2 p-value= 0.03 and 0.04, respectively). As is shown in this Table the mean age for men, T-Stage and pretreatment PSA levels among men treated in the VLBST group was similar to other groups. Patients in the VLBST group had a similar median follow up of 7.2 years, compared to 7.1, 7.3 and 7.2 years in patients with low, average or high testosterone.
The results of heterogeneity testing are shown in Table 3 . The six arms from the two studies (RTOG 9202 and 9413) were homogeneous with respect to the hazard ratios (HRs) of OS, DM, BF, and CSS (all p-values > 0.05). These tables show the pooled HR of testosterone groups VLBST (RL) vs. LBST vs. ABST vs. HBST) of each outcome with and without adjusting for other covariates. None of the outcomes show a statistically significant difference among the four BST groups because the 95% CI of each HR included 1. The results from univariate proportional hazards analyses of the overall impact of baseline testosterone level on OS, DM, BF, and CSS are summarized in Table 4 . None of the outcomes show statistically significant differences (p-values >0.05), which is the same as the results from the pooled HRs.
The multivariate analysis for OS, DM, BF and CSS are summarized in Tables 5a-d. The multivariate analysis for OS is shown in Table 5a . Age < 70, Gleason score 2-6, KPS of 100 were independently associated with an OS advantage. Of note, pretreatment PSA ≥ 20 ng/ml and Arm 3 of RTOG 9413 were marginally associated with worse OS (p=0.07). The multivariate analysis for DM is shown in Table 5b . Age <70, Gleason score > 2-6, PSA ≥ 20 ng/ml were independently associated with an increased risk of DM (p<0.0001, 0.004, <0.0001, and 0.01, for age, Gleason 7 and 8-10, and PSA ≥ 20 ng/ml, respectively. In addition, reductions in the risk of DM were noted by treatment arms, for RTOG 9202 Arm 2, RTOG Arms 1, 2, 3, and 4 compared to Arm 1 of RTOG 9202 (p <0.001, <0.001, 0.01, p=0.06 and 0.002, respectively). The multivariate analysis for this BF is shown in Table 5c . Age < 70, Gleason score > 2-6, and PSA ≥ 10 ng/ml were independently associated with an increased risk of BF (p<0.0001, 0.0004 and <0.0001, and <0, <0001 and <0.0001 for age, Gleason 7 and 8-10 and PSA ≥10-<20 and ≥20 ng/ml, respectively). Differences were also noted by treatment arms, for RTOG 9202 Arm 2, and RTOG Arms 1, 3, and 4 compared to Arm 1 of RTOG 9202 (p <0.0001, 0.0005, p=0.009 and 0.0002, respectively). The multivariate analysis for this CSS is shown in Table 5d . Age < 70, Gleason score > 7, and PSA ≥ 20 ng/ml were all independently associated with a reduced CSS (p=0.0005, <0.0001, and p=0.02, for age, GS 8-10 and PSA ≥ 20 ng/ml, respectively). Differences were also noted by treatment arms, for RTOG 9202 Arm 2, and RTOG Arms 1, 2, 3, and 4 compared to Arm 1 of RTOG 9202 (p=0.03, 0.0002, p=0.04, p=0.02 and 0.001, respectively). Of note however, the BST group was not statistically significantly associated with any of the outcomes studied (p-values >0.05).
Discussion
Testosterone levels alone are not considered adequate for diagnosing hypogonadism but men with a total testosterone less than 200 ng/dl with symptoms are usually considered candidates for testosterone replacement therapy 24 , 25. Other studies define androgendeficient levels as a total testosterone less than 320 ng/dl 26. In this study we chose to define a low serum testosterone level as less than or equal to 314 ng/dl but greater than 248 ng/dl. Those with a very low baseline serum testosterone (VLBST) were defined as less than or equal to 248 ng/dl. Thus our criteria for low and very low are not inconsistent with the literature even though they were chosen based on the distribution of values (lowest tertile) observed. In this study we found no association between the baseline serum testosterone level and outcome. This observation was unexpected given the fact that some studies suggest that a low baseline serum testosterone might be associated with an increased mortality rate independent of a diagnosis of prostate cancer 27 , 28. Our findings are consistent with a review of testosterone levels and aging published by the Institute of Medicine (2004) that concluded "Endogenous testosterone levels clearly decline with aging, but it is not clear if lower levels of serum testosterone affect health outcomes in older men" 24.
To our knowledge this is the largest prospective analysis of the pre-treatment significance of the baseline serum testosterone in men treated on prospective phase III randomized trials for clinically localized prostate cancer. Prior studies have been complicated by small sample sizes, retrospective selection of data, and inclusion of heterogeneous patient groups, (some with metastatic disease and others with localized disease). In this analysis we evaluated all cause survival, distant metastatic disease, biochemical (PSA) failure and prostate cancer specific survival. We observed no relationship between baseline testosterone level and OS, CSS, DM or PSA failure. We did however observe that that older men tend to have less aggressive prostate cancer. This finding is consistent with the results of a study in which men were treated by radical prostatectomy and raises unanswered questions about potential mechanisms 29 . Not surprisingly, the pretreatment PSA and Gleason score were also major predictors of cause specific survival (Table 5d ).
Recent studies support the health benefits of addressing hypogonadism. For example, Coward et al. recently described the outcomes of 81 hypogonadal men (mean age 56.8 years) treated with testosterone replacement therapy 30. With a mean follow-up of 33.8 months (range, 6-144) they noted that after starting testosterone replacement therapy the total cholesterol improved from 203.8 to 166.6 mg/dL (P < 0.05) after 36 months, and the incidence of prostate cancer among men appears to be no greater than that in the general population. Our findings provide additional support for the growing body of literature questioning the merits of withholding testosterone replacement therapy in men with prostate cancer 31. For example, Morgentaler recently reviewed the scientific and ethical considerations associated with testosterone replacement therapy. He highlighted the fact that due to the saturation of the androgen receptor binding capacity, higher concentrations of androgen do not results in greater androgen binding and discussed a body of literature that demonstrates a lack of correlation with PSA levels and the risk of prostate cancer. He also summarized the findings from 3 series that reported the outcomes of patients treated (surgery, in two series and brachytherapy) for prostate cancer who subsequently under went testosterone replacement therapy 32 -34. In his review he noted biochemical recurrences in only 1.8% of men (2 of 111) who received testosterone replacement therapy, which would appear to be a lower rate of recurrence than usually observed 35. More recently still, Morales et al. have reported on five men with testosterone deficiency syndrome (TDS) after external beam radiotherapy (EBRT) for localized prostate cancer who were treated with testosterone once their PSAs had reached their nadir 36. With a follow-up of 14.5 months (6-27) one of the patients had a transitory increase in PSA level but none had levels of >1.5 ng/mL. The patients generally reported marked improvement in hot flushes, fatigue, and libido, with two reporting improved erectile function.
There are a number of potential limitations to our study. First, it is possible that only men with extremely low levels of testosterone might have more aggressive disease. To test this hypothesis we re-ran our analysis defining very low risk as the lowest 5% (n=124) but also saw no evidence that this subset was any different than the bottom 16.5% used in this analysis (data not shown). Perhaps with longer follow-up an impact on survival would appear, but this seems unlikely since patients with androgen independent usually have a much shorter survival than those with androgen dependent disease. The fact that no differences were seen in biochemical (PSA) failure based on the baseline testosterone level would also seem to make this possibility very unlikely.
Another potential limitation is that this study may not be generalized to all men with prostate cancer because the current study can only help answer the questions regarding baseline testosterone levels in prostate cancer patients undergoing EBRT and ADT. It is possible that these findings should not be extrapolated to men managed with radiation therapy alone. However, since androgen deprivation therapy is thought to be neither indicated nor beneficial in low risk patients there is no obvious reason to suspect that the findings would be different for this subset of patients. The continuation of testosterone replacement therapy in low-risk patients would theoretically be safer than in intermediate-risk and high-risk patients because of their lower risk of death from prostate cancer. However, since low-risk patients were not included in this study, we have no direct evidence that low risk patient can safely continue testosterone replacement therapy during radiotherapy. Based on our data, one can simply conclude that BST levels did not affect prognosis. Of note however, is the recent report by Taira et al. that suggests that our conclusions may be equally relevant to low risk patients 37 . To our knowledge no one in the RTOG plans to test the hypothesis that testosterone replacement therapy during radiotherapy improves the quality of life of low-risk prostate cancer patients.
Another limitation of this study is that based on our data we are unable to answer the questions as to whether hormone replacement therapy should be discontinued in newly diagnosed patients or whether when treatment is completed, whether replacement therapy should be reinstituted. It seems logical to assume however, that since BST does not impact outcome, then a newly diagnosed patient with low risk disease (for whom ADT would not be indicated) could probably safely continue testosterone replacement therapy. The issue of re-initiating testosterone after completion of treatment in a patient whose treatment includes ADT is more problematic because it is sometime difficult to determine disease free status in a patient with a low serum testosterone.
In conclusion, we were unable to confirm the assertion that men with very low baseline testosterone levels have more aggressive prostate cancer. Since baseline serum testosterone levels do not appear to influence clinically significant outcomes in men with intermediate to high risk disease and in light of other recent observations we question the common practice of recommending discontinuation of testosterone replacement therapy in all men with newly diagnosed low risk prostate cancer. The point is, a mildly hypogonadal state is probably inadequate protection against the growth of occult metastatic disease, while a normal level may be no more dangerous and may be associated with an improvement in quality of life. In contrast however, patients with metastatic disease may require castrate levels to be spared the sequel of disease progression. Without Missing Data 2478 * Actuarial estimates for overall survival (OS) were calculated using the Kaplan-Meier method, and the cumulative incidence method was used to estimate biochemical failure (BF), distant metastasis (DM), and cause-specific survival (CSS). ** Hazard ratio: A hazard ratio quantifies how much more or less risk patients at some level have than those at the reference level (RL). A confidence interval that includes 1 indicates no difference between these two subgroups. † OS : p-value from Chi-square test using the Cox-proportional hazards model; BF, DM, CSS : p-value from log-rank/Gray's test statistics for testing whether the two groups have the same survival distribution or not.
Table 2
Pretreatment Characteristics By Baseline Serum Testosterone (n=2478) * The Kaplan-Meier method was used to estimate overall survival, and the cumulative incidence method was used to estimate local failure, distant metastasis, and cause-specific survival. ** Hazard ratio: A hazard ratio quantifies how much more (less) risk patients at some level have than those at the reference level (RL). A confidence interval that includes 1 indicates no difference between these two subgroups. † For overall survival, the p-value is from the Chi-square test using the Cox-proportional hazards model; for all other endpoints, the p-value is from log-rank/Gray's test statistics for testing whether the two groups have the same survival distribution or not. 
